Prospective Comparison of Sorafenib and Sunitinib for Second-Line Treatment of Cytokine-Refractory Kidney Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|74|3-4|216-222

ISSN： 0030-2414

Source： Oncology, Vol.74, Iss.3-4, 2008-08, pp. : 216-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

By  

Oncology, Vol. 67, Iss. 5-6, 2005-02 ,pp. : 376-381

Karger

Access to resources Recommend Favorite

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 435-443

Karger

Access to resources Recommend Favorite

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 99-102

Karger

Access to resources Recommend Favorite

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite